ArticleThe British journal of radiology2022
Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer.
Article in The British journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Diagnostic performance of magnetic resonance imaging-based radiomics for detecting prostate cancer: A systematic review and meta-analysis.World journal of radiology · 2026Article
- Combining multi-parametric MRI radiomics features with tumor abnormal protein to construct a machine learning-based predictive model for prostate cancer.Scientific reports · 2025Article
- Article
- Prediction of prostate cancer aggressiveness using magnetic resonance imaging radiomics: a dual-center study.Discover oncology · 2024Article
- Virtual biopsy in abdominal pathology: where do we stand?BJR open · 2023Review
- More than Meets the Eye: Using Textural Analysis and Artificial Intelligence as Decision Support Tools in Prostate Cancer Diagnosis-A Systematic Review.Journal of personalized medicine · 2022Review
- Innovations in prostate cancer: introductory editorial.The British journal of radiology · 2022Article
- Prediction of clinically significant prostate cancer with a multimodal MRI-based radiomics nomogram.Frontiers in oncology · 2022Article
- Utility of Clinical-Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions.Frontiers in oncology · 2022Article
- Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders.Cancer genomics & proteomicsArticle
- Radiomics in prostate cancer: an up-to-date review.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and validate a non-invasive MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer (PCa) prior to therapy.
methodsIn all, 139 qualified and pathology-confirmed PCa patients were divided into a training set (
resultsNine radiomics features were identified to form the radiomics signature. The radiomics score (Rad-score) was significantly different between indolent and aggressive PCa (
conclusionThe multiparametric MRI-based radiomics signature can potentially serve as a non-invasive tool for distinguishing between indolent and aggressive PCa prior to therapy. ADVANCES IN KNOWLEDGE: The multiparametric MRI-based radiomics signature has the potential to non-invasively distinguish between the indolent and aggressive PCa, which might aid clinicians in making personalized therapeutic decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.